Deborah Keller

Laboratory Corporation of America has named Deborah Keller as the CEO of Covance Drug Development. She takes over for Joseph Herring who will retire on July 31 after more than a decade as CEO.

Keller joined Covance in 1987 and has held senior leadership roles in global operations, quality assurance, and marketing. Most recently she served as executive vice president of Covance and group president of R&D Laboratories where she led more than 6,000 employees at 18 facilities across the globe.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.